Drug search by name

Darunavir Tablets and Victrelis

Determining the interaction of Darunavir Tablets and Victrelis and the possibility of their joint administration.

Check result:

Darunavir Tablets <> Victrelis

Relevance: 17.05.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Talk to your doctor before using boceprevir together with darunavir. Combining these medications may reduce the blood levels of both medications, which may make them less effective in the treatment of hepatitis C and HIV infection. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Let your doctor know if your conditions worsen during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Coadministration of boceprevir with cobicistat-boosted or ritonavir-boosted regimens of atazanavir, darunavir, or lopinavir may result in decreased plasma concentrations of both boceprevir and the protease inhibitors. The mechanism of interaction has not been described. In a pharmacokinetic study of 39 healthy volunteers, boceprevir reduced the mean trough plasma concentrations (Cmin) of ritonavir-boosted atazanavir, darunavir, and lopinavir by 49%, 59%, and 43%, respectively. Mean reductions of 34% to 44% were observed in the systemic exposure (AUC) and 25% to 36% were observed in the peak concentration (Cmax) of atazanavir, lopinavir, and darunavir. Conversely, cobicistat-boosted and ritonavir-boosted atazanavir did not alter the AUC of boceprevir, whereas ritonavir-boosted darunavir and lopinavir decreased the AUC of boceprevir by 32% and 45%, respectively.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, the use of boceprevir in combination with ritonavir-boosted or cobicistat-boosted regimens of atazanavir, darunavir, or lopinavir is not recommended. Moreover, the safety and efficacy of boceprevir has not been established in the HCV/HIV coinfected population.

References

"Product Information. Victrelis (boceprevir)." Schering-Plough Corporation, Kenilworth, NJ.
Cerner Multum, Inc. "Australian Product Information." O 0
Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Important drug interactions between (boceprevir) and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitor drugs. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm291119.htm." ([2012 Feb 8]):
"Product Information. Evotaz (atazanavir-cobicistat)." Bristol-Myers Squibb, Princeton, NJ.

Darunavir Tablets

Generic Name: darunavir

Brand name: Prezista

Synonyms: Darunavir

What is Darunavir Tablets?

Victrelis

Generic Name: boceprevir

Brand name: Victrelis

Synonyms: n.a.

What is Victrelis?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions